Born to survive: how cancer cells resist CAR T cell therapy
Jean Lemoine(Université Sorbonne Paris Nord), Roch Houot(Inserm)
Cited by 121
Related Papers
Prognostic impact of<i>DDX41</i>germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study
|Blood|2022|80
Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study
|Blood Advances|2021|51
EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models
|Cancer Cell|2025|47
R-CHOP14 As a Standard of Care in Primary Mediastinal B Cell Lymphoma: A 10-YEARS Experience of Lysa Centers
|Blood|2020|3
OUTCOMES AFTER FIRST‐LINE IMMUNOCHEMOTHERAPY FOR PRIMARY MEDIASTINAL B CELL LYMPHOMA PATIENTS: A LYSA STUDY
|Hematological Oncology|2021|0